{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:49:00Z","timestamp":1790732940566,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12879-016-1344-2","type":"journal-article","created":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T10:12:11Z","timestamp":1454321531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury"],"prefix":"10.1186","volume":"16","author":[{"given":"Wan Soo","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Yoon","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Hyo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woon Tae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ok Jae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Woo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Seon","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Chin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,1]]},"reference":[{"issue":"4","key":"1344_CR1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1164\/rccm.167.4.603","volume":"167","author":"HM Blumberg","year":"2003","unstructured":"Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167(4):603\u201362.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1344_CR2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.phrs.2004.10.009","volume":"51","author":"M Sharifzadeh","year":"2005","unstructured":"Sharifzadeh M, Rasoulinejad M, Valipour F, Nouraie M, Vaziri S. Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberculosis [correction of antituberclosis] treatment. Pharmacol Res. 2005;51(4):353\u20138.","journal-title":"Pharmacol Res"},{"issue":"7","key":"1344_CR3","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1164\/rccm.2108091","volume":"166","author":"SK Sharma","year":"2002","unstructured":"Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med. 2002;166(7):916\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1344_CR4","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1086\/422645","volume":"39","author":"R Hest van","year":"2004","unstructured":"van Hest R, Baars H, Kik S, van Gerven P, Trompenaars MC, Kalisvaart N, et al. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. Clin Infect Dis. 2004;39(4):488\u201396.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1344_CR5","first-page":"534","volume":"9","author":"JR Tost","year":"2005","unstructured":"Tost JR, Vidal R, Cayla J, Diaz-Cabanela D, Jimenez A, Broquetas JM, et al. Severe hepatotoxicity due to anti-tuberculosis drugs in Spain. Int J Tuberc Lung Dis. 2005;9(5):534\u201340.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"1344_CR6","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1164\/rccm.201105-0850OC","volume":"185","author":"A Singanayagam","year":"2012","unstructured":"Singanayagam A, Sridhar S, Dhariwal J, Abdel-Aziz D, Munro K, Connell DW, et al. A comparison between two strategies for monitoring hepatic function during antituberculous therapy. Am J Respir Crit Care Med. 2012;185(6):653\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"1344_CR7","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","volume":"174","author":"JJ Saukkonen","year":"2006","unstructured":"Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935\u201352.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1344_CR8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0962-8479(96)90098-2","volume":"77","author":"M Dossing","year":"1996","unstructured":"Dossing M, Wilcke JT, Askgaard DS, Nybo B. Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis. 1996;77(4):335\u201340.","journal-title":"Tuber Lung Dis"},{"issue":"2","key":"1344_CR9","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/thx.51.2.132","volume":"51","author":"JN Pande","year":"1996","unstructured":"Pande JN, Singh SP, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: a case\u2013control study. Thorax. 1996;51(2):132\u20136.","journal-title":"Thorax"},{"issue":"12","key":"1344_CR10","first-page":"1499","volume":"8","author":"A Fernandez-Villar","year":"2004","unstructured":"Fernandez-Villar A, Sopena B, Fernandez-Villar J, Vazquez-Gallardo R, Ulloa F, Leiro V, et al. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis. 2004;8(12):1499\u2013505.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1344_CR11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/hep.510310129","volume":"31","author":"WM Wong","year":"2000","unstructured":"Wong WM, Wu PC, Yuen MF, Cheng CC, Yew WW, Wong PC, et al. Antituberculosis Drug-Related Liver Dysfunction in Chronic Hepatitis B Infection. Hepatology. 2000;31:201\u20136.","journal-title":"Hepatology"},{"issue":"12","key":"1344_CR12","doi-asserted-by":"crossref","first-page":"e83892","DOI":"10.1371\/journal.pone.0083892","volume":"8","author":"N Lomtadze","year":"2013","unstructured":"Lomtadze N, Kupreishvili L, Salakaia A, Vashakidze S, Sharvadze L, Kempker RR, et al. Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis. PLoS One. 2013;8(12):e83892.","journal-title":"PLoS One"},{"issue":"6 Pt 1","key":"1344_CR13","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1164\/ajrccm.157.6.9711039","volume":"157","author":"JR Ungo","year":"1998","unstructured":"Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med. 1998;157(6 Pt 1):1871\u20136.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1344_CR14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1440-1746.2012.07279.x","volume":"28","author":"H Devarbhavi","year":"2013","unstructured":"Devarbhavi H, Singh R, Patil M, Sheth K, Adarsh CK, Balaraju G. Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury. J Gastroenterol Hepatol. 2013;28(1):161\u20137.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"1344_CR15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s15010-007-6125-9","volume":"35","author":"A Fernandez-Villar","year":"2007","unstructured":"Fernandez-Villar A, Sopena B, Garcia J, Gimena B, Ulloa F, Botana M, et al. Hepatitis C virus RNA in serum as a risk factor for isoniazid hepatotoxicity. Infection. 2007;35(4):295\u20137.","journal-title":"Infection"},{"issue":"1","key":"1344_CR16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00408-013-9535-8","volume":"192","author":"YM Liu","year":"2014","unstructured":"Liu YM, Cheng YJ, Li YL, Liu CE, Hsu WH. Antituberculosis treatment and hepatotoxicity in patients with chronic viral hepatitis. Lung. 2014;192(1):205\u201310.","journal-title":"Lung"},{"issue":"4","key":"1344_CR17","first-page":"1304","volume":"127","author":"B-H Lee","year":"2005","unstructured":"Lee B-H, Koh W-J, Choi M-S, Suh G-Y, Chung M-P, Kim H-j, et al. Inactive HBsAg carrier state and hepatotoxicity during antiTB chemotherapy. Chest. 2005;127(4):1304\u201311.","journal-title":"Chest"},{"issue":"3","key":"1344_CR18","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1378\/chest.06-2042","volume":"131","author":"YS Kwon","year":"2007","unstructured":"Kwon YS, Koh WJ, Suh GY, Chung MP, Kim H, Kwon OJ. Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy. Chest. 2007;131(3):803\u20138.","journal-title":"Chest"},{"key":"1344_CR19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1440-1746.1997.tb00353.x","volume":"12","author":"HWANG S-J","year":"1997","unstructured":"S-J HWANG, J-C WU, C-N LEE, F-S YEN, C-L LU, T-P LIN, et al. A prospective clinical study of isoniazid-rifampicin-pyrazinamideinduced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol. 1997;12:87\u201391.","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"1344_CR20","first-page":"332","volume":"14","author":"L Castro de","year":"2010","unstructured":"de Castro L, Do Brasil PE, Monteiro TP, Rolla VC. Can hepatitis B virus infection predict tuberculosis treatment liver toxicity? Development of a preliminary prediction rule. Int J Tuberc Lung Dis. 2010;14(3):332\u201340.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1344_CR21","first-page":"12","volume-title":"Korea Centers for Disease Control & Prevention: YANG Byung-guk","author":"G Un-yeoung","year":"2012","unstructured":"Un-yeoung G, Hyun-jin S, Yeon-kyeng L, Hyosoon Y, Yoon-sung P, Hae-young K, et al. Annual report on the notified tuberculosis in korea. In: Prevention KCfDC, editor. Korea Centers for Disease Control & Prevention: YANG Byung-guk. 2012. p. 12."},{"issue":"1","key":"1344_CR22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000252780","volume":"53","author":"NH Park","year":"2010","unstructured":"Park NH, Chung YH, Lee HS. Impacts of vaccination on hepatitis B viral infections in Korea over a 25-year period. Intervirology. 2010;53(1):20\u20138.","journal-title":"Intervirology"},{"issue":"2","key":"1344_CR23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3350\/cmh.2014.20.2.89","volume":"20","author":"The Korean Association for the Study of the L","year":"2014","unstructured":"The Korean Association for the Study of the L. KASL clinical practice guidelines: Management of Hepatitis C. Clin Mol Hepatol. 2014;20(2):89\u2013136.","journal-title":"Clin Mol Hepatol"},{"issue":"9","key":"1344_CR24","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/j.1478-3231.2011.02526.x","volume":"31","author":"CW Wang","year":"2011","unstructured":"Wang CW, Lin HY, Shin SJ, Yu ML, Lin ZY, Dai CY, et al. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population. Liver Int. 2011;31(9):1326\u201331.","journal-title":"Liver Int"},{"issue":"3","key":"1344_CR25","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1440-1746.2007.04824.x","volume":"22","author":"G Tarantino","year":"2007","unstructured":"Tarantino G, Saldalamacchia G, Conca P, Arena A. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. J Gastroenterol Hepatol. 2007;22(3):293\u2013303.","journal-title":"J Gastroenterol Hepatol"},{"key":"1344_CR26","unstructured":"Moon H, Lee J. Korean Guidelines for Tuberculosis. Korea: Joint Committee for the Development of Korean Guidelines for Tuberculosis; 2011."},{"key":"1344_CR27","unstructured":"WHO: Treatment of tuberculosis guidelines, 4th ed. Geneva, World Health Organization, 2010 (WHO\/HTM\/STB\/2009.420). Available: http:\/\/whqlibdoc.who.int\/publications\/2010\/9789241547833_eng.pdf ."},{"issue":"3","key":"1344_CR28","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jceh.2012.07.007","volume":"2","author":"RK Dhiman","year":"2012","unstructured":"Dhiman RK, Saraswat VA, Rajekar H, Reddy C, Chawla YK. A Guide to the Management of Tuberculosis in Patients with Chronic Liver Disease. J Clin Exp Hepatol. 2012;2(3):260\u201370.","journal-title":"J Clin Exp Hepatol"},{"issue":"1","key":"1344_CR29","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jhep.2008.08.023","volume":"50","author":"I Wedemeyer","year":"2009","unstructured":"Wedemeyer I, Bechmann LP, Odenthal M, Jochum C, Marquitan G, Drebber U, et al. Adiponectin inhibits steatotic CD95\/Fas up-regulation by hepatocytes: therapeutic implications for hepatitis C. J Hepatol. 2009;50(1):140\u20139.","journal-title":"J Hepatol"},{"issue":"6","key":"1344_CR30","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S0168-8278(99)80325-0","volume":"31","author":"S Schenker","year":"1999","unstructured":"Schenker S, Martin RR, Hoyumpa AM. Antecedent liver disease and drug toxicity. J Hepatol. 1999;31(6):1098\u2013105.","journal-title":"J Hepatol"},{"issue":"2","key":"1344_CR31","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1440-1746.2007.05207.x","volume":"23","author":"A Tostmann","year":"2008","unstructured":"Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008;23(2):192\u2013202.","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"1344_CR32","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0929-6646(09)60040-1","volume":"108","author":"H-Y Sun","year":"2009","unstructured":"Sun H-Y, Chen I-L, Gau C-S, Chang S-C, Luh K-T. A Prospective Study of Hepatitis During Antituberculous Treatment in Taiwanese Patients and a Review of the Literature. J Formos Med Assoc. 2009;108(2):102\u201311.","journal-title":"J Formos Med Assoc"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-016-1344-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T00:56:59Z","timestamp":1498265819000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomedcentral.com\/1471-2334\/16\/50"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1344"],"URL":"https:\/\/doi.org\/10.1186\/s12879-016-1344-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,1]]},"article-number":"50"}}